Alpine Global Management’s Protalix BioTherapeutics PLX Stock Holding History

Alpine Global Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-1,200	Closed	-$22K	–	461
2014 Q4	$22K	Buy	+1,200	New	+$25.8K	﹤0.01%	575

Other funds holding PLX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

MTWSIF

Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

Alpine Global Management's PLX Position: Q1 2015 in Review

Alpine Global Management sold out of Protalix BioTherapeutics (PLX) in Q1 2015, closing a stake of 1,200 shares — an estimated $22K sold.

Alpine Global Management first reported a position in PLX in Q4 2014 and held it in 1 quarter. The position peaked at $22K in Q4 2014. 37 funds tracked by Wall St. Rank hold PLX as of Q1 2015.

Alpine Global Management reported no remaining Protalix BioTherapeutics position as of Q1 2015 after selling out during the quarter.
Alpine Global Management sold 1,200 Protalix BioTherapeutics shares in Q1 2015, an estimated $22K.
Alpine Global Management first reported a position in Protalix BioTherapeutics in Q4 2014 and held it in 1 quarter.
Alpine Global Management's Protalix BioTherapeutics position peaked at $22K in Q4 2014.
37 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2015.

Based on Alpine Global Management's 13F filing for Q1 2015, filed 5 May 2015.